PRECLINICAL CHARACTERIZATION OF THRX-113587: A NOVEL, POTENT AND SELECTIVE INHIBITOR FOR THE NOREPINEPHRINE TRANSPORTER

被引：0
|
作者：
Shen, F.
Smith, J.
Tsuruda, P.
Stangeland, E.
McNamara, A.
Cremers, T.
Martin, W.
机构：
来源：
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY | 2014年 / 115卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
463
引用
收藏
页码：141 / 141
页数：1
相关论文
共 50 条
  • [1] Preclinical characterization of tunlametinib, a novel, potent, and selective MEK inhibitor
    Liu, Yahong
    Cheng, Ying
    Huang, Gongchao
    Xia, Xiangying
    Wang, Xingkai
    Tian, Hongqi
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [2] Discovery of WAY-260022, a Potent and Selective Inhibitor of the Norepinephrine Transporter
    Gavrin, Lori K.
    Mahaney, Paige E.
    Jenkins, Douglas
    Nogle, Lisa M.
    Mugford, Cheryl A.
    Huselton, Christine
    Leiter, Jennifer
    Johnston, Grace H.
    Bray, Jenifer A.
    Burroughs, Kevin D.
    Cosmi, Scott A.
    Alfinito, Peter
    Ho, Douglas M.
    Deecher, Darlene C.
    Trybulski, Eugene J.
    ACS MEDICINAL CHEMISTRY LETTERS, 2010, 1 (03): : 91 - 95
  • [3] Identification and characterization of a potent and selective inhibitor of human urate transporter 1
    Ting Wu
    Jiasheng Chen
    Shuai Dong
    Haixin Li
    Ying Cao
    Yuanxin Tian
    Weimin Fu
    Pingzheng Zhou
    Baomin Xi
    Jianxin Pang
    Pharmacological Reports, 2017, 69 : 1103 - 1112
  • [4] Identification and characterization of a potent and selective inhibitor of human urate transporter 1
    Wu, Ting
    Chen, Jiasheng
    Dong, Shuai
    Li, Haixin
    Cao, Ying
    Tian, Yuanxin
    Fu, Weimin
    Zhou, Pingzheng
    Xi, Baomin
    Pang, Jianxin
    PHARMACOLOGICAL REPORTS, 2017, 69 (05) : 1103 - 1112
  • [5] Preclinical in vivo characterization of INCB028060, a novel, potent and highly selective c-Met inhibitor
    Koblish, H. K.
    Liu, X.
    Hall, L.
    Boer, J.
    He, C.
    Yeleswaram, S.
    Newton, R. C.
    Vaddi, K.
    Yao, W.
    Scherle, P. A.
    Fridman, J. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [6] Preclinical characterization of HMPL-295, a potent and selective ERK 1/2 inhibitor
    Hu, Jia
    Ni, Jun
    Lv, Yuanzhi
    Li, Wenjun
    Zhang, Hui
    Li, Xin
    Yu, Ying
    Zhong, Zeyu
    Wang, Jian
    Sai, Yang
    Qing, Weiguo
    Ren, Yongxin
    Shi, Michael
    Su, Weiguo
    CANCER RESEARCH, 2024, 84 (06)
  • [7] Discovery of a potent and selective Axl inhibitor in preclinical model
    Inoue, Satoshi
    Yamane, Yoshinobu
    Tsukamoto, Shuntaro
    Azuma, Hiroshi
    Nagao, Satoshi
    Murai, Norio
    Nishibata, Kyoko
    Fukushima, Sayo
    Ichikawa, Kenji
    Nakagawa, Takayuki
    Sugi, Naoko Hata
    Ito, Daisuke
    Kato, Yu
    Goto, Aya
    Kakiuchi, Dai
    Ueno, Takashi
    Matsui, Junji
    Matsushima, Tomohiro
    BIOORGANIC & MEDICINAL CHEMISTRY, 2021, 39
  • [8] Preclinical Characterization of Linrodostat Mesylate, a Novel, Potent, and Selective Oral Indoleamine 2,3-Dioxygenase 1 Inhibitor
    Balog, Aaron
    Lin, Tai-An
    Maley, Derrick
    Gullo-Brown, Johnni
    Kandoussi, Enzo Hamza
    Zeng, Jianing
    Hunt, John T.
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (03) : 467 - 476
  • [9] Preclinical identification of AZD7762, a novel, potent and selective inhibitor of Checkpoint kinases
    Ashwell, Susan
    Caleb, Benjamin L.
    Deng, Chun
    Green, Stephen
    Grondine, Michael R.
    Haye, Heather R.
    Horn, Candice L.
    Janetka, James W.
    Liu, Dongfang
    Mouchet, Elizabeth
    Ready, Shannon
    Rosenthal, Judith L.
    Queva, Christophe
    Taylor, Karen J.
    Sheehy, Adam M.
    Walker, Graeme E.
    White, Anne M.
    Zabludoff, Sonya D.
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3411S - 3411S
  • [10] Discovery and preclinical evaluation of a novel highly selective and potent CDK12 inhibitor
    Yamakawa, Hiroko
    Mizutani, Akio
    Arikawa, Yasuyoshi
    Ebara, Shunsuke
    Satoh, Yoshihiko
    Morishita, Daisuke
    CANCER SCIENCE, 2023, 114 : 831 - 831
12345